Back

Featured Topics

Behind The Science
Breast Cancer
Cancer Immunotherapy
Hematology
Lung Cancer
Manufacturing
Multiple Sclerosis
Oncology
Ophthalmology
Partnering
Respiratory Health
Rheumatology
About Us Contact Us Leadership Awards & Recognition Investors Suppliers Compliance
  • Share
  • Twitter
  • Facebook
  • LinkedIn
  • Heart
  • Twitter
  • Facebook
  • LinkedIn

Our Approach to Hematology


Read More Stories
Dec 6, 2013

Nancy Valente, M.D.

Vice President, Global Hematology Development, Genentech


Hematology medicines are never one-size-fits-all. We at Genentech are proud of our contributions to the treatment of blood diseases, but we know that many patients need new options. That's why we're working harder than ever to develop the next generation of medicines. Drawing on great scientific progress that has redefined the way we think about blood cancers and disorders, we're exploring new molecular targets and strategies to fight these devastating diseases in new ways.

Our approved and investigational medicines are born from science and are designed to work in a variety of ways.

For blood cancers, one approach is to deliver chemotherapy directly to cancer cells by using antibody-drug conjugates (ADCs). Antibodies' ability to hone in on specific targets may mean less damage to the rest of the body's cells.

Antibodies are also the basis for anti-CD20 therapies, which are designed to hunt down the cells that comprise certain lymphomas and leukemias based on a specific marker (CD20) on their surface. These antibodies are designed to eliminate cancer cells by harnessing the body's own defense system: immune cells. Anti-CD20 antibodies can also kill cancer cells directly.

Antibodies are powerful tools precisely because they can recognize one target among billions. At the same time, we know that many blood disorders, such as hemophilia A, involve more than one mechanism or pathway. Bispecific antibodies can help address this by recognizing and binding to two different targets.

Two other approaches for blood cancers involve signaling pathways within the cancer cell itself. One strategy is to block cancer's ability to thrive - i.e., signals that tell cancer cells to grow, survive, and spread. Our other strategy is to trigger cancer cell suicide. This process, known as apoptosis, can be initiated by many different signals. Targeting such signals is a major strategy in our hematology pipeline.

Together, these approaches and others on the horizon are bringing new hope to people with blood cancers and disorders. While one size certainly doesn't fit all, someday we just might have enough sizes to fit every one.

We are using multiple approaches for our approved and investigational hematology medicines:

   of  

Tags:

  • Hematology,
  • Hemophilia

Read More Stories

Read about breakthrough science, the everyday people who make it happen, and the patients we serve.

?? of 40 moments published

  • Diversity & Inclusion
  • Chief Diversity Officer
  • Fostering Belonging
  • Advancing Inclusive Research & Health Equity
  • Transforming Society
  • Our Work in Action
  • Now Hiring
  • Work Here
  • Find A Job
  • University & Early Career
  • Professional Areas
  • For Scientists
  • Our Scientists
  • Publications
  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
  • For Patients
  • Our Medicines
  • Our Approach to Pricing
  • Financial Support
  • Medicine Information Support
  • Investigational Medicines
  • Genentech Patient Foundation
  • Disease Education
  • Advancing Inclusive Research
  • For Medical Professionals
  • Our Medicines & Products
  • Our Pipeline
  • Medical Resources
  • Sunshine Act Compliance
  • Product Security
  • For Partners
  • Our Approach
  • What We Are Looking For
  • Partner With Us
  • Our Stories
  • For Media
  • News Features
  • Press Releases
  • Statements
  • Company Information
  • Sign Up For News Alerts
  • For Good
  • Local Initiatives
  • Giving
  • Environmental Sustainability
  • About Us
  • Leadership
  • Awards & Recognition
  • Investors
  • Suppliers
  • Our Approach to Pricing
  • CA Transparency in Supply
  • Compliance Overview
  • Contact Us
  • Call Us
  • Email Us
  • Visit us
  • Submit a Medical Inquiry
  • Submit a Media Inquiry
  • Privacy
  • Privacy Policy
  • Terms & Conditions
© 2021 Genentech, Inc. All rights reserved. This site is intended for US residents only.